Loading...
NPI 1154492247 · Garden City, NY · Clinical Pathology/Laboratory Medicine Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Ann Anderson is a clinical pathology/laboratory medicine physician provider located in Garden City, New York. This profile covers 17 Medicare and 9 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Ann Anderson |
| Address | 700 Stewart Ave Ste 101 |
| City | Garden City |
| State | NY |
| ZIP | 11530 |
| Taxonomy | Clinical Pathology/Laboratory Medicine Physician |
| NPI Enumerated | November 13, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.2M |
| Medicaid | $0 |
ANN ANDERSON is operating clearly as a high-volume molecular diagnostics laboratory within the Clinical Pathology/Laboratory Medicine taxonomy: the Medicare top codes are dominated by amplified nucleic acid probe tests and high-complexity gene sequencing. Key contributors include 87798 (43.8K claims, $1.5M revenue, 29.1% of Medicare revenue), 87150 (40.2K claims, $1.4M revenue, 26.7%), and 81162 (543 claims, $970.9K revenue, 19.0%), indicating routine infectious-agent molecular testing alongside substantial hereditary cancer sequencing work.
Revenue is highly concentrated: the three top Medicare codes account for 74.8% of this provider’s total Medicare revenue, signaling dependence on a narrow set of molecular and sequencing services. That concentration suggests programmatic specialization where a small number of test types drive most topline Medicare billing.
Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $5.2M while reported Medicaid revenue is $0, so the provider lacks a Medicaid billing footprint. This asymmetry means payor diversification risk is concentrated entirely on Medicare reimbursement and demand dynamics.
The provider shows notable national standing on several codes. 81162 ranks #4 of 35 providers nationally (91th percentile; notably above typical national volume for this code), 87150 ranks #11 of 190 (95th percentile; typical, unremarkable volume), and 87798 ranks #43 of 1319 (97th percentile; typical, unremarkable volume), which together indicate above-average to leading volume positions in both BRCA sequencing and amplified-probe infectious testing.
Certain lines are statistical outliers for physician interpretation and reporting volume: G0452 has 3.9K claims, $156.7K revenue (3.1% of Medicare revenue) and ranks #3 of 614 providers nationally (100th percentile; extreme outlier, far above typical national volume). Multiple amplified-probe infectious-agent codes (for example 87556 at 3.4K claims, $137.5K revenue; 87651 at 3.4K claims, $114K revenue) also rank in high percentiles (93th–99th percentiles) and are described as notably above typical or high-volume versus peers.
The provider combines high per-claim revenue sequencing with low-per-claim infectious testing: 81162 average paid/claim is $1788 and 81307 average paid/claim is $663 versus many amplified-probe tests paid around $34–$41 per claim. This split—few high-dollar sequencing claims plus large volumes of low-dollar probe tests—explains how BRCA and other sequencing codes can drive a large share of total revenue despite smaller claim counts.
ANN ANDERSON appears to occupy niche, limited-peer segments for some high-complexity tests: 81408 is listed with 11 claims, $21.6K revenue and ranks #1 of 1 providers nationally (0th percentile; no national peer volume comparison available), while multiple hereditary cancer genes (e.g., 81162, 81307) are served by relatively few providers nationally. That limited peer set for tiered molecular codes indicates participation in specialized genetic testing markets with constrained competition.
The provider has long tenure in enrollment: NPI enumerated 2006-11-13 (~20 years ago), which paired with sustained multi-year Medicare billing suggests an established laboratory practice. Longevity plus the observed code mix and high national ranks for select services point to an enduring specialization in molecular and genetic diagnostics.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 43,810 | $30 | $1.5M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 40,240 | $30 | $1.4M |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 540 | $1,790 | $970.9K |
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 550 | $660 | $367.3K |
| G0452 | Molecular pathology procedure; physician interpretation and report | 3,920 | $40 | $156.7K |
| 87556 | The lab analyst performs a test for Mycobacterium tuberculosis using amplified nucleic acid probe technique. Mycobacteria tuberculosis are sometimes called acid fast bacteria because of the special… | 3,350 | $40 | $137.5K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 3,350 | $30 | $114K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 3,350 | $30 | $114K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 3,350 | $30 | $114K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 3,350 | $30 | $114K |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 200 | $0 | $0 |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 200 | $0 | $0 |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 200 | $0 | $0 |
| 87556 | The lab analyst performs a test for Mycobacterium tuberculosis using amplified nucleic acid probe technique. Mycobacteria tuberculosis are sometimes called acid fast bacteria because of the special… | 200 | $0 | $0 |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 200 | $0 | $0 |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 200 | $0 | $0 |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 200 | $0 | $0 |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 330 | $0 | $0 |
| G0452 | Molecular pathology procedure; physician interpretation and report | 200 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
9 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 107 | 200 | 340 | $40 | $170.7K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 201 | 320 | 500 | $30 | $82.6K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 61 | 100 | 300 | $30 | $67.5K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 42 | 70 | 300 | $20 | $29.7K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 6 | 20 | 30 | $20 | $21.4K |
| 87556 | The lab analyst performs a test for Mycobacterium tuberculosis using amplified nucleic acid probe technique. Mycobacteria tuberculosis are sometimes called acid fast bacteria because of the special… | 10 | 10 | 310 | $30 | $20.1K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 13 | 30 | 150 | $30 | $17.8K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 25 | 50 | 210 | $10 | $17.6K |
| G0452 | Molecular pathology procedure; physician interpretation and report | 6 | 10 | 170 | $30 | $12.7K |
Other providers in the same ZIP code as Ann Anderson, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Regioncare Inc. | NY | Home Health Agency | $0 | $96.6M |
| Bethpage Medical, PLLC | NY | Obstetrics & Gynecology Physician | $0 | $32M |
| Sco Family Of Services | NY | Foster Care Agency | $0 | $27.1M |
| Endo Group, LLC | NY | Ambulatory Surgical Clinic/Center | $3.7M | $1.4M |
| Endoscopy Center Of Long Island LLC | NY | Ambulatory Surgical Clinic/Center | $1.2M | $1.5M |
| Mark Fleckner | NY | Retina Specialist (Ophthalmology) Physician | $1.9M | $172.3K |
| Robin Ehrenpreis | NY | Diagnostic Radiology Physician | $1.6M | $0 |
| Paul Lang | NY | Nuclear Radiology Physician | $1.3M | $70.2K |
| Richard Jacaruso | NY | Cardiovascular Disease Physician | $1.1M | $0 |
| Carina Rizzo | NY | Dermatology Physician | $1.1M | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.